Conclusions
- Immunotherapy remains ineffective for patients with MSS CRC.
- There is an association between FOLFOX and high tumor infiltrating CD8+ T cell levels.
- CD8+ T cell levels and PD-L1 expression do not predict survival in FOLFOX-treated patients.
- There is an association between high PDL1+ rates and RCRC, BRAF-mut CRC, and FOLFIRI-treated L-CRC.
Future Directions
- We are currently investigating:
- Various chemotherapy + immunotherapy treatment schedules in vivo to identify optimal strategies for patients with MSS CRC.
- Immune cell activation state along the course of chemotherapy treatment in patients with MSS CRC.